Skip to main content
. 2020 Mar 5;2020:5617192. doi: 10.1155/2020/5617192

Figure 3.

Figure 3

IFN-γ makes hMSCs capable of inhibiting MRL.Faslpr B cells. (a, b) hMSCs (0.003–0.1 × 105 cells/well) and MRL.Faslpr mouse B (a) or T (b) cells (1 × 105 cells/well) were cocultured for 72 h. B cells with lipopolysaccharide (LPS, 1 μg/ml) and T cells were activated with concanavalin A (ConA, 1 μg/ml). Proliferation of B and T cells was measured by the 3H-thymidine uptake assay (upper), and the levels of IgM (a) and IFN-γ (b) accumulated in culture medium were measured by ELISA (lower). (c–f) hMSCs were pretreated with IFN-γ (3–30 ng/ml) for 7 days (c, e) or with IFN-γ (10 ng/ml) for 1–7 days (d, f). hMSCs (0.1 × 105 cells/well) and B cells (1 × 105 cells/well) were cocultured for 72 h, and the levels of IgM were measured by ELISA (c, d). hMSCs (0.1 × 105 cells/well) and T cells (1 × 105 cells/well) were cocultured for 72 h, and the levels of IFN-γ accumulated in culture medium were measured by ELISA (e, f). ∗p < 0.01 versus control.